Kestra Medical Revenue Beats Estimates, But Soaring Costs Drive Wide Earnings Miss

Kestra Medical Technologies (KMTS) reported strong top-line results that beat analyst expectations on September 14, but a significant earnings miss driven by escalating costs created a mixed picture for investors. The stock initially fell approximately 9.4% in after-hours trading before staging a partial recovery the following day, highlighting investor uncertainty over the company's spending.

Strong Growth Met with Rising Costs

Kestra delivered robust growth and operational improvements that confirmed some of its strategic goals. However, the positive developments were overshadowed by concerns about the company's expense management.

Key figures from the quarter include:

• Revenue: $31.0 million, a 60% year-over-year increase that surpassed the consensus estimate of $29.0 million.
• Gross Margin: Expanded to 56.5%, an increase of 1,080 basis points from 45.7% in the prior-year period, marking the tenth straight quarter of sequential improvement.
• Adjusted EPS: A loss of -$0.75 per share, missing the estimated loss of -$0.45 by a wide margin.
• Operating Expenses: Surged 46.4% year-over-year to $55.2 million, with the pace of spending outrunning revenue growth.

Ad

Despite the earnings miss, management signaled confidence in its sales trajectory by raising its full-year 2027 revenue guidance to $141 million from a previous $137 million. The company also strengthened its balance sheet by securing a new $200 million non-dilutive term loan in July, bringing its total liquidity to approximately $320 million.

Investor Focus Shifts to Profitability

The market's reaction underscores a core tension between Kestra's aggressive investment in growth and the demand for a clearer path to profitability. While the company is successfully expanding its commercial footprint, aided by positive clinical data and new payer agreements, investors are now focused on its ability to control costs.

Upcoming catalysts that will be closely watched include a planned reveal of a late-stage R&D project next quarter and the company's Q2 earnings report in December. Analysts will be looking for evidence of operating leverage and discipline on OpEx growth. Management has guided for a path to EBITDA breakeven in fiscal years 2028-2029, and any deviation from that timeline could significantly impact the stock.